Literature DB >> 23969617

An analysis of factors related to recurrence of myxofibrosarcoma.

Kazutaka Kikuta1, Daisuke Kubota, Akihiko Yoshida, Yoshihisa Suzuki, Hideo Morioka, Yoshiaki Toyama, Eisuke Kobayashi, Fumihiko Nakatani, Hirokazu Chuuman, Akira Kawai.   

Abstract

OBJECTIVE: Myxofibrosarcoma is clinically characterized by a high frequency of local recurrence after surgery. To improve the clinical outcome of patients with myxofibrosarcoma, it is imperative to control any postsurgical local recurrence.
METHODS: In this study, we performed a retrospective clinicopathologic analysis of 100 consecutive patients with myxofibrosarcoma to identify factors related to poor prognosis. All of the patients had been diagnosed, and had undergone surgery at the National Cancer Center Hospital between 1999 and 2008.
RESULTS: At the initial visit to our hospital, 64 patients had primary myxofibrosarcoma, whereas 36 had undergone primary unplanned resection at other facilities. Of the 36 patients, 11 consulted our hospital before recurrence and 25 did so after recurrence. A histologically positive margin after surgery was evident in 28% of the cases overall. The estimated 5-year recurrence-free survival rate was 74.8%. Univariate analysis showed that primary unplanned resection at another facility (P = 0.0001) and a histologically positive margin (P = 0.0224) were significant predictors of local recurrence. When these two factors were subjected to multivariate analysis, only primary unplanned resection at another facility was significantly correlated with the estimated recurrence-free survival rate (P = 0.0011). Primary unplanned resection was also significantly related to the 5-year disease-free survival rate (P = 0.0401).
CONCLUSIONS: Our findings indicate that primary unplanned resection at a non-referral hospital is the most important risk factor related to poor prognosis of myxofibrosarcoma. Accurate diagnosis and adequate initial surgery are most important factors for improving the clinical outcomes of myxofibrosarcoma.

Entities:  

Keywords:  myxofibrosarcoma; recurrence; surgery

Mesh:

Year:  2013        PMID: 23969617     DOI: 10.1093/jjco/hyt119

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  16 in total

1.  Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.

Authors:  Ann Y Lee; Narasimhan P Agaram; Li-Xuan Qin; Deborah Kuk; Christina Curtin; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2016-01-12       Impact factor: 5.344

2.  An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI.

Authors:  Kazutaka Kikuta; Daisuke Kubota; Akihiko Yoshida; Hideo Morioka; Yoshiaki Toyama; Hirokazu Chuuman; Akira Kawai
Journal:  Skeletal Radiol       Date:  2014-08-30       Impact factor: 2.199

Review 3.  Extremity Soft Tissue Sarcoma: Role of Local Control.

Authors:  Elyse J Brinkmann; Safia K Ahmed; Matthew T Houdek
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

Review 4.  Diagnosis and Management of Subcutaneous Soft Tissue Sarcoma.

Authors:  Makoto Endo; Nokitaka Setsu; Toshifumi Fujiwara; Takeaki Ishii; Makoto Nakagawa; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Yasuharu Nakashima; Yoshihiro Matsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

5.  Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.

Authors:  Atsushi Yamashita; Yoshiyuki Suehara; Takuo Hayashi; Tatsuya Takagi; Daisuke Kubota; Keita Sasa; Nobuhiko Hasegawa; Muneaki Ishijima; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2022-06-15       Impact factor: 4.535

Review 6.  Percutaneous biopsy of musculoskeletal tumors and the potential for needle tract seeding: technical considerations, current controversies, and outcomes.

Authors:  Cara Lai; Jeremiah R Long; Brandon T Larsen; Jose M Iturregui; Benjamin K Wilke; Krista A Goulding
Journal:  Skeletal Radiol       Date:  2022-10-18       Impact factor: 2.128

7.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 8.  Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy.

Authors:  Fien Hoefkens; Charlotte Dehandschutter; Johan Somville; Paul Meijnders; Dirk Van Gestel
Journal:  Radiat Oncol       Date:  2016-10-12       Impact factor: 3.481

9.  Distant metastasis in patients with myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Mitsunori Kaya; Hiroyuki Nagasawa; Makoto Emori; Yasutaka Murahashi; Emi Mizushima; Naohisa Miyakoshi; Toshihiko Yamashita; Yoichi Shimada
Journal:  Ups J Med Sci       Date:  2017-08-17       Impact factor: 2.384

10.  MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases.

Authors:  Shirong Ma; Linni Fan; Yixiong Liu; Yingmei Wang; Kangjie Yu; Lifeng Wang; Na Fang; Fang Liu; Shuangping Guo; Zhe Wang
Journal:  Diagn Pathol       Date:  2018-08-21       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.